This report summarizes the proceedings for Day 3 of the workshop titled “ Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls”. From a drug product quality perspective, patient-centric product development necessitates the development of clinically relevant drug product specifications (CRDPS). In this regard, Physiologically Based Biopharmaceutics modeling (PBBM) is a viable tool to establish links between in-vitro to in-vivo data, and support with establishing CRDPS. The theme of day 3 was practical applications of PBBM to support drug product quality. In this manuscript, case studies from US FDA, EMA and pharmaceutical industry on applications of PBBM in drug product quality are summarized which include 1) regulatory agency’s perspectives on establishing the safe space and achieving study waivers, 2) model-informed risk assessment on the effects of acid reducing agents, bridging of dissolution methods, food effect, and formulation selection, and 3) understanding clinical formulation performance. Breakout session discussions focused on four topics – 1) terminologies related to physiologically based modeling in support of drug product quality, 2) regulatory harmonization on evidentiary standards, 3) CRDPS approaches and 4) bridging between biorelevant and quality control (QC) dissolution methods.
By Amitava Mitra, Sandra Suarez-Sharp, Xavier J.H. Pepin, Talia Flanagan, Yang Zhao, Evangelos Kotzagiorgis
Neil Parrott, Satish Sharan, Christophe Tistaert, Tycho Heimbach, Banu Zolnik, Erik Sjogren, Fang Wu, Om Anand, Shefali Kakar
Min Li, Shereeni Veerasingham, Shinichi Kijima, Gustavo Mendes Lima Santos, Baoming Ning, Kimberly Raines, Greg Rullo
Haritha Mandula, Poonam Delvadia, Jennifer Dressman, Paul A. Dickinson, Andrew Babiskin